Balloon Atrial Septostomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Balloon atrial septostomy (BAS) — the Rashkind procedure — is a life-saving interventional cardiac procedure that uses a catheter-mounted balloon to tear the atrial septum and create a controlled inter-atrial communication. Described by William Rashkind and William Miller at the Children's Hospital of Philadelphia in 1966, it transformed the management of cyanotic congenital heart disease before cardiac surgery was sufficiently developed to offer early definitive repair. Today it remains the most important catheter palliation for neonates with transposition of the great arteries (TGA) and other mixing-dependent cyanotic heart defects.

In transposition of the great arteries, the aorta arises from the right ventricle and the pulmonary artery from the left ventricle — creating two parallel, non-communicating circulations. Deoxygenated blood cycles from the body through the right heart to the aorta and back to the body without oxygenation, while oxygenated blood cycles from the lungs through the left heart to the pulmonary artery and back to the lungs. Life is possible only if there is some communication between the two circulations — through the foramen ovale, ductus arteriosus, or a ventricular septal defect. When the foramen ovale is restrictive and the ductus begins to close in the first days of life, neonates with TGA become critically hypoxaemic and die without urgent intervention.

BAS is performed at the bedside under echocardiographic guidance in the neonatal intensive care unit, or in the cardiac catheterisation laboratory. A balloon-tipped catheter is advanced from the umbilical vein or femoral vein into the right atrium, passed through the foramen ovale into the left atrium, inflated to approximately 12–15 mm, and forcibly withdrawn into the right atrium — tearing the thin septum primum flap. The resulting unrestrictive inter-atrial communication allows mixing of oxygenated and deoxygenated blood, raising arterial oxygen saturation to viable levels.

Transposition of the great arteries (TGA) with restrictive inter-atrial communication is the classic indication for emergency BAS. Neonates present in the first hours to days of life with severe progressive cyanosis — oxygen saturation often below 50% — tachypnoea, and cardiovascular collapse. Prostaglandin E1 infusion to maintain ductal patency provides some mixing but is insufficient when the foramen ovale is restrictive; BAS creates a reliable, larger inter-atrial shunt to stabilise the neonate until arterial switch operation can be performed.

Total anomalous pulmonary venous drainage (TAPVD) with obstruction and intact atrial septum may require BAS as a decompressive emergency before surgical correction. Hypoplastic left heart syndrome with restrictive atrial septum — a common cause of early neonatal death before staged palliation — requires urgent BAS or surgical atrial septectomy to allow adequate pulmonary venous egress. In adults with severe pulmonary arterial hypertension (PAH) and failing right ventricle, graded balloon atrial septostomy (with progressively larger balloons) creates a palliative right-to-left shunt that decompresses the right heart and maintains systemic output.

Neonates with confirmed TGA and clinical evidence of restrictive inter-atrial communication — progressive cyanosis despite prostaglandin E1, arterial pO2 below 3 kPa, oxygen saturation below 65–70% on full inspiratory support, or echocardiographic evidence of restrictive foramen ovale — require immediate BAS. The procedure can be performed at the bedside under echocardiographic guidance without the need to transport the critically unstable neonate to the catheterisation laboratory.

In adults with PAH, candidacy for graded BAS is established by NYHA class III–IV symptoms, recurrent syncope despite maximised PAH-targeted pharmacotherapy, resting oxygen saturation above 90% on room air (sufficient reserve to tolerate induced right-to-left shunt), and mean right atrial pressure below 20 mmHg. Eisenmenger syndrome (already established right-to-left shunt) is not an indication for BAS, as the physiological effect is already present. Significant left ventricular dysfunction is a contraindication as the right-to-left shunt would increase preload on an already compromised LV.

Standard balloon atrial septostomy (Rashkind technique) is performed using a balloon septostomy catheter (Miller-Edwards or Cook BAS catheter) passed from the femoral or umbilical vein via the inferior vena cava into the right atrium and through the foramen ovale into the left atrium. The balloon is inflated with contrast-saline solution to the recommended diameter (typically 12–15 mm in neonates) and withdrawn sharply and forcibly through the septum. The manoeuvre is repeated 2–3 times to maximise the resulting defect size.

Blade atrial septostomy uses a Park blade catheter, which carries a small retractable blade at its tip, to make controlled incisions in the septum before BAS — required in neonates with a thick or fibrous septum or in older infants and adults where the septum is too tough to tear with balloon alone. Radiofrequency wire perforation of the intact atrial septum facilitates crossing when the foramen ovale is not patent. Blade BAS is technically more demanding and carries slightly higher perforation risk than standard BAS. In adults with PAH, graded BAS uses incrementally larger balloon sizes across multiple sessions to achieve optimal haemodynamic effect.

Selecting the most appropriate Balloon Atrial Septostomy approach requires a structured assessment of patient-specific factors. The treating specialist evaluates disease severity, prior treatment history, comorbidities, and patient preferences before recommending a specific protocol. Combination approaches are often more effective than monotherapy — integrating pharmacological, procedural, or rehabilitative elements to address multiple disease mechanisms simultaneously. Dose or intensity is titrated incrementally based on clinical response, tolerability, and objective outcome measures. In patients with refractory disease or inadequate response to first-line protocols, escalation to higher-intensity or specialist-delivered treatment options is indicated. Multidisciplinary team (MDT) review ensures that surgical, medical, and allied health perspectives are integrated into the final management plan, particularly for complex or high-risk cases where multiple treatment pathways are viable and the risk-benefit balance requires careful deliberation.

In neonates with TGA, successful BAS raises arterial oxygen saturation from critical levels (30–60%) to viable mixing levels (70–90%) within minutes of the procedure, allowing stabilisation and transfer for definitive arterial switch operation within 2 weeks. When performed promptly, BAS virtually eliminates early neonatal mortality from TGA-related acute hypoxaemia. The arterial switch operation — now performed at 3–14 days of age — carries 97–98% early survival at experienced congenital cardiac surgery centres, with children achieving normal cardiac anatomy and near-normal long-term outcomes.

In adults with severe PAH, BAS achieves acute increases in cardiac index of 25–50%, significant reduction in right atrial pressure, and subjective improvement in dyspnoea and syncope frequency. Observational series report 1-year survival of 60–75% following BAS in patients with refractory PAH, superior to historical survival without intervention. Quality of life improvement — particularly elimination of syncopal episodes — is a consistent and meaningful patient-reported benefit.

BAS in neonates with TGA is a relatively safe procedure with a procedural mortality below 1% in experienced centres when performed before severe metabolic acidosis has developed. Cardiac perforation (right atrial or pulmonary venous) occurs in under 0.5% of cases and can cause pericardial tamponade requiring emergency drainage. Inadvertent mitral valve injury can impair left ventricular filling. Vascular access complications (femoral artery or vein laceration) may require surgical repair.

In adults with PAH, BAS carries a procedural mortality of 5–15% reflecting the extreme haemodynamic fragility of these patients. Acute catastrophic right-to-left shunting leading to severe systemic hypoxaemia and cardiac arrest is the most feared complication if the created defect is too large for the patient's reserve. Paradoxical embolism via the new right-to-left shunt is a risk in patients with concurrent pulmonary thrombus. Staged graded BAS with careful haemodynamic monitoring reduces but does not eliminate this risk.

After neonatal BAS for TGA, the infant is stabilised in the neonatal cardiac intensive care unit on prostaglandin E1, oxygen, and inotropic support as required. Echocardiography confirms adequate inter-atrial defect size immediately post-procedure and re-assesses if oxygen saturation deteriorates. Arterial switch operation is planned within 7–14 days while the left ventricle is still conditioned to pump against systemic pressure. Post-operative recovery from ASO requires 2–3 weeks of NICU care.

For adults following graded BAS for PAH, haemodynamic monitoring in the cardiac ICU is maintained for 24–72 hours with continuous oxygen saturation monitoring, pulmonary artery pressure assessment, and cardiac output measurement. Continuing PAH-targeted medical therapy is essential. Follow-up echocardiography and right heart catheterisation at 3–6 months assesses haemodynamic response and defect stability. Lung transplantation planning should be expedited for eligible patients as the definitive therapy.

Neonatal BAS is an emergency procedure and costs are incorporated into the overall management cost of TGA, which includes NICU care, BAS, and arterial switch operation — totalling USD 80,000–180,000 in the United States. For adult PAH patients, graded BAS as part of a comprehensive PAH management programme at a specialist pulmonary hypertension centre typically costs USD 30,000–70,000 in the US.

JCI-accredited paediatric cardiac centres in India perform BAS and subsequent arterial switch operation at total costs of approximately USD 10,000–20,000. Thailand's leading cardiac centres manage TGA at USD 20,000–35,000. For adult PAH requiring BAS, specialist centres in India offer graded septostomy at USD 5,000–10,000. These centres have experienced paediatric interventional cardiologists, modern catheterisation and echocardiography equipment, and dedicated neonatal cardiac ICUs.

For neonates with TGA and restricted inter-atrial communication, blade atrial septostomy or surgical atrial septectomy (Blalock-Hanlon procedure) are alternatives to balloon septostomy for a thick septum that cannot be torn with a standard balloon. In current practice, surgical septectomy is rarely needed as blade septostomy and radiofrequency perforation techniques have largely replaced it.

The definitive alternative to palliation is immediate arterial switch operation, which some centres now perform within 24–48 hours of birth without initial septostomy when the anatomy is favourable and haemodynamics are stable on prostaglandin. For adult PAH, escalating combination pharmacotherapy (triple combination of prostacyclin analogue, ERA, and PDE5 inhibitor) and lung transplantation are the primary alternatives to BAS, with BAS serving as palliation or bridge to transplant.